Arkolith/Insider Trading/XFOR/Form 4

DiBiase Mary

Chief Operating OfficerX4 Pharmaceuticals, Inc (XFOR) · full profile →Form 4 · filed Nov 2, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 31, 2023Grant(A)231K—$0379K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-23-036459) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML